Lazard Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $766K | Sell |
35,571
-151,930
| -81% | -$3.27M | ﹤0.01% | 1378 |
|
|
2025
Q1 | $3.11M | Buy |
187,501
+36,573
| +24% | +$607K | ﹤0.01% | 828 |
|
|
2024
Q4 | $2.77M | Buy |
150,928
+53,885
| +56% | +$988K | ﹤0.01% | 779 |
|
|
2024
Q3 | $1.49M | Buy |
97,043
+63,211
| +187% | +$971K | ﹤0.01% | 950 |
|
|
2024
Q2 | $549K | Buy |
33,832
+7,619
| +29% | +$124K | ﹤0.01% | 1165 |
|
|
2024
Q1 | $483K | Buy |
26,213
+17,719
| +209% | +$326K | ﹤0.01% | 1064 |
|
|
2023
Q4 | $265K | Buy |
8,494
+2,133
| +34% | +$66.5K | ﹤0.01% | 1300 |
|
|
2023
Q3 | $132K | Buy |
6,361
+2,236
| +54% | +$46.4K | ﹤0.01% | 1527 |
|
|
2023
Q2 | $98K | Buy |
4,125
+1,088
| +36% | +$25.8K | ﹤0.01% | 1585 |
|
|
2023
Q1 | $57K | Buy |
+3,037
| New | +$57K | ﹤0.01% | 1751 |
|
|
2022
Q4 | – | Sell |
-3,689
| Closed | -$60K | – | 2356 |
|
|
2022
Q3 | $60K | Buy |
+3,689
| New | +$60K | ﹤0.01% | 1710 |
|
|
2022
Q1 | – | Sell |
-3,115
| Closed | -$72K | – | 2304 |
|
|
2021
Q4 | $72K | Buy |
3,115
+506
| +19% | +$11.7K | ﹤0.01% | 1570 |
|
|
2021
Q3 | $43K | Buy |
+2,609
| New | +$43K | ﹤0.01% | 1743 |
|
|
2021
Q1 | – | Sell |
-1,356
| Closed | -$72K | – | 1834 |
|
|
2020
Q4 | $72K | Hold |
1,356
| – | – | ﹤0.01% | 1277 |
|
|
2020
Q3 | $55K | Buy |
+1,356
| New | +$55K | ﹤0.01% | 1157 |
|
|
2020
Q2 | – | Sell |
-4,060
| Closed | -$171K | – | 1601 |
|
|
2020
Q1 | $171K | Sell |
4,060
-57,786
| -93% | -$2.43M | ﹤0.01% | 920 |
|
|
2019
Q4 | $2.65M | Buy |
61,846
+61,031
| +7,488% | +$2.61M | ﹤0.01% | 632 |
|
|
2019
Q3 | $29K | Buy |
+815
| New | +$29K | ﹤0.01% | 1027 |
|